Semax is a peptide nootropic drug developed in Russia. It marketed as drops for intranasal administration. Semax is used to treat cerebrovascular conditions (such as stroke), increase mental capacity and improve cognition (including in healthy adults).
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Semax is a peptide nootropic drug, developed in the Soviet Union. It is long-acting synthetic analog of adrenocorticotropic hormone (ACTH), a polypeptide tropic hormone naturally occurring in the human brain.
The drug has pronounced nootropic properties and is shown to improve memory, attention, and the ability of the brain to resist stressful conditions such as hypoxia, ischemia and traumatic injuries.
As of today, semax approved for medical use in Russia to treat various neurological conditions including traumatic brain injuries, cerebrovascular diseases, encephalopathy, and ADHD. It is also used recreationally as a nootropic drug for cognition-improving purposes in healthy adults.
Indications for use as suggested by the manufacturer are as follows:
- Memory and attention impairments
- Mental fatigue
- Brain injuries complication
- Residual effects of traumatic brain injuries and neurosurgical interventions
- Optic nerve atrophy, optic neuritis, glaucoma, and diabetic retinopathy
- Minor brain dysfunctions in children, including ADHD
- Acute phase of ischemic stroke (for 1% semax)
No customer reviews for the moment.
Dosage and Administration
Semax is applied intranasally.
Memory impairment - 3 drops in each nasal passage 2 times a day for 10 days, 2 courses per year are recommended.
Chronic brain ischemia, astheno-neurotic disorders - 3 drops in each nasal passage for 16 days, 2-4 courses per year are recommended.
Stroke Prevention and TIA - 3 drops in each nasal passage 2 times a day for 10 days, 2 courses per year are recommended.
Recovery period after stroke and TIA - 4 drops in each nasal passage 6 times a day for 16 days.
Preventing (preventing) recurrent strokes and TIA - 3 drops in each nasal passage 3 times a day for 16 days, 2-3 courses per year are recommended.
Traumatic brain injury and neurosurgical operations - 3 drops in each nasal passage 3 times a day for 16 days, a repeated course is recommended after 6 months.
Treatment of post-anesthetic disorders of memory and attention - 3 drops in each nasal passage 3 times a day for 6 days.
Minimal brain dysfunction in children, including attention deficit hyperactivity disorder (ADHD) - 2 drops in each nasal passage 3 times a day for 20 days, 2-4 courses per year are recommended.
Glaucoma, atrophy of the optic nerve - 2 drops in each nasal passage 3 times a day for 20 days, 2-4 courses per year are recommended.
Improving performance, improving memory, reducing stress - 3 drops in each nasal passage 2 times a day for 10 days, 1-2 courses per year are recommended.
With prolonged use: possibly - slight irritation of the nasal mucosa.
- Hypersensitivity to the drug;
- acute psychotic states, disorders accompanied by anxiety;
- pregnancy, breastfeeding;
- endocrine diseases.
Considering the way of administration of Semax (intranasal), it is undesirable to administer agents with local vasoconstrictor action when administered intranasally.
Pregnancy and Lactation
Contraindicated in pregnancy and lactation.
- Brand name: Semax
- Active ingredient: Methionyl-glutamyl-histidyl-phenylalanyl-prolyl-glycyl-proline
- Dosage form: Nasal drops.
- Manufacturer: Peptogen
- Country of Origin: Russia
- Synthetic acth analogue semax displays nootropic-like activity in humans
- Effect of semax heptapeptide on rat heart activity during acute hypobaric hypoxia in the early postnatal period
- In vivoefficiency of Semax in global cerebral ischemia
- Relationship between therapeutic effect of the peptide preparation semax and severity of brain ischemia
- Effect of semax heptapeptide on the human electroencephalogram
- Analgesic action of the new drug Semax
- Effect of semax and ACTH (5–10) on electrical activity of central neurons
- Effect of semax on homeostasis of gastric mucosa in albino rats
- Degradation of the ACTH(4-10) analog Semax in the presence of rat basal forebrain cell cultures and plasma membranes
- C-Terminal Pro-Gly-Pro Tripeptide in Contrast to Full-Length Neuropeptide Semax Exhibits No Neuroprotective Effect in Experimental Cerebral Ischemia
- Effects of semax against the background of dopaminergic receptor blockade with haloperidol
- Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex
- Comparative study of analgesic potency of ACTH4–10fragment and its analog semax
- Effects of semax and its Pro-Gly-Pro fragment on calcium homeostasis of neurons and their survival under conditions of glutamate toxicity
- Audiogenic epilepsy in young mice of different strains after neonatal semax treatment
- Anticoagulation and Antiplatelet Effects of Semax under Conditions of Acute and Chronic Immobilization Stress
- Effect of Modification of the N-Terminal Region of Semax on the Expression of Nootropic Effect of Semax Analogs
- Semax and Pro-Gly-Pro Activate the Transcription of Neurotrophins and Their Receptor Genes after Cerebral Ischemia
- Luminescence analysis of blood components in studies of the neuroprotective properties of the drug “Semax” in cerebral ischemia
- Semax, An ACTH(4-10) Analogue with Nootropic Properties, Activates Dopaminergic and Serotoninergic Brain Systems in Rodents
- Comparison of the Temporary Dynamics of NGF and BDNF Gene Expression in Rat Hippocampus, Frontal Cortex, and Retina Under Semax Action
- The Effect of Semax and Its C-End Peptide PGP on the Morphology and Proliferative Activity of Rat Brain Cells During Experimental Ischemia: A Pilot Study
- Semax, an analogue of adrenocorticotropin (4–10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain
- Conformational transitions in the nootropic peptide semax (MEHFPGP) and its N-terminal modifications